ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a strong ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full ... at our inaugural R&D Day in June.” ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Hello, and welcome to the Acadia Healthcare fourth quarter 2024 ...

2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a strong note ...

Detailed price information for Acadia Healthcr Company (ACHC-Q) from The Globe and Mail including charting and trades.

ACADIA’s financial performance in the fourth quarter of 2024 demonstrated resilience ... The company plans to host its inaugural R&D Day in June 2025, which may provide further insights into ...

R&D expenses in 2025 are projected to be in the ... in the third quarter of 2025. During the reported quarter, Acadia signed an exclusive worldwide license agreement with Saniona, a Denmark ...

ACADIA’s financial performance in the fourth quarter of 2024 demonstrated resilience ... The company plans to host its inaugural R&D Day in June 2025, which may provide further insights into its ...